News | February 20, 2015

Scientists Use MRI to Visualize Pancreas Inflammation in Early Type 1 Diabetes

Technique could be used to predict likelihood of developing diabetes, improve treatment

February 20, 2015 — A pilot study led by researchers at Joslin Diabetes Center has revealed that it is possible to use magnetic resonance imaging (MRI) to "see" the inflammation in the pancreas that leads to type 1 diabetes. This discovery could be a boon for research on methods to slow or halt the disease at an early stage, and could also guide insights into how diabetes progresses.

The clinical study, published in the Proceedings of the National Academy of Sciences, tested the possibility of imaging inflammation in the pancreas of human volunteers using ferumoxytol, a coated iron nanoparticle approved by the U.S. Food and Drug Administration (FDA) as an iron replacement therapy, and MRI. Ferumoxytol leaks out of blood vessels in areas of inflammation and is taken up by immune cells called macrophages, which congregate at sites of inflammation. (AMAG Pharmaceuticals, which markets ferumoxytol under the name Feraheme, was not involved in the study.)

Autoimmunity and inflammation directed against the pancreas and its insulin-producing beta cells underlie the development of type 1 diabetes. However, while tests for autoantibodies (antibodies against the pancreas) can reveal whether a patient's immune system has at some point attacked the pancreas, these antibodies are not always a good marker for predicting whether a given individual will develop full-blown diabetes.

"Many people have genetic variants that put them at risk for type 1 diabetes," explained study co-lead author Jason Gaglia, M.D., M.M.Sc., an assistant investigator in the Section of Immunobiololgy at Joslin. "Some develop autoimmunity, but only a small number develop clinical disease."

In addition, the development of therapies that could potentially halt patients' progression from pancreatic inflammation to diabetes has been hampered by the long lead times needed in order to tell whether a given therapy has an effect.

"If you want to study in people an immunodulatory agent right now, for diabetes it takes years," Gaglia said. He explained that the end measurements for whether such therapies work relate directly to pancreatic function, changes in which may not become apparent for a long time. With imaging, he continued, "you could have an answer in a matter of months."

For the study, Gaglia and his collaborators — including study co-lead author Mukesh Harisinghani, M.D., of Massachusetts General Hospital — recruited 11 patients with newly diagnosed type 1 diabetes and evidence of antibodies against the pancreas. They also recruited 10 controls with no sign or family history of diabetes.

To visualize inflammation across the whole pancreas, the researchers adapted MRI mapping algorithms originally developed for whole brain scanning. All other components of the experiment, including MRI equipment and ferumoxytol, are widely available.

Gaglia notes that the ferumoxytol dose used in this imaging study is approximately one quarter of the dose used therapeutically for iron replacement. "These are all off-the-shelf components," he said. "Other centers can do this now."

Ferumoxytol-MRI images of the patient group showed clear evidence of ferumoxytol accumulation in the pancreas, indicating ongoing inflammation. By comparison, images from the control group did not.

The researchers believe this imaging technique could have a range of applications in diabetes research and help build a better understanding of the natural history of type 1 diabetes. Already, Gaglia said, the ferumoxytol-MRI images revealed that in their patient group, "inflammation was not uniform across the entire pancreas. There was also a large amount of variation between individuals, which aligns with what you see clinically. That’s never been shown in living humans before."

This imaging approach could also, in the future, help better define which patients with autoimmunity will likely progress to diabetes and classify subgroups of patients who might benefit from different therapeutic strategies. It could also identify those patients with early signs of autoimmunity who might be good candidates for clinical research studies.

"Only about 5 percent of the first-degree family members of a person with diabetes will develop occult disease," Gaglia, who is firm that for the moment this imaging technique should only be used in the context of research. "It might make sense to scan people in that group to see who is likely to progress and who isn’t. Those who are progressing may be the ones you would want to recruit for research on immunomodulatory therapies."

For more information: www.joslin.org

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Carestream Launches MR Brain Perfusion and Diffusion Modules for Vue PACS
Technology | Advanced Visualization | August 16, 2017
Carestream Health recently introduced new MR (magnetic resonance) Brain Perfusion and MR Brain Diffusion modules that...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
GE Healthcare's Signa Premier MRI Receives FDA 510(k) Clearance
Technology | Magnetic Resonance Imaging (MRI) | August 04, 2017
GE Healthcare announced Signa Premier, a new wide bore 3.0T magnetic resonance imaging (MRI) system, is now available...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area

NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area. Image courtesy of David Vaillancourt, Ph.D., University of Florida.

News | Neuro Imaging | July 31, 2017
Scientists at the University of Florida have discovered a new method of observing the brain changes caused by Parkinson...
Overlay Init